38 commercial payer policies list J2182. See each policy's status for the code and its official source. Listing a code is not a coverage decision: read each policy’s source for the requirements that apply.
Free account. Policy pages stay open to everyone.
38 policies from 17 payers
Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
Codes labeled “Inferred from policy title” are not listed in the policy document; Backwork attached them because the policy title names the drug.
Showing 10 of 13 · All EviCore by Evernorth policies
| Policy | Effective | Status of J2182 |
|---|---|---|
| Mepolizumab (Nucala) | May 1, 2022 | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Mepolizumab (Nucala) | Aug 1, 2019 | Prior auth requiredInferred from policy title |
| Mepolizumab (Nucala) | Jan 1, 2020 | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
|---|
| Mepolizumab (Nucala) | Jun 1, 2021 | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
|---|
| Mepolizumab (Nucala) | May 15, 2018 | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
|---|
| Mepolizumab (Nucala) | Aug 1, 2018 | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
|---|
| Mepolizumab (Nucala) | Jul 1, 2020 | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
|---|
| Mepolizumab (Nucala) | May 1, 2023 | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
|---|
| Nucala (mepolizumab) | Oct 1, 2025 | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
|---|
| Nucala (mepolizumab) | Apr 1, 2024 | Prior auth requiredInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
|---|
| Policy | Effective | Status of J2182 |
|---|---|---|
| Provider Administered Drugs – Site of Care | Oct 1, 2026 | Covered |
| Respiratory Interleukin-5 Inhibitor | Oct 1, 2026 | Covered |
| Respiratory Interleukins (Cinqair, Fasenra, & Nucala) – Community Plan Medical Benefit Drug Policy | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Respiratory Interleukins (Cinqair, Fasenra, & Nucala) – Individual Exchange Medical Benefit Drug Policy | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2182 |
|---|---|---|
| Mepolizumab | Jun 15, 2026 | Covered |
| Specialty Medication Administration Site of Care | Jan 1, 2026 | Covered |
| Policy | Effective | Status of J2182 |
|---|---|---|
| Mepolizumab | Jun 15, 2026 | Covered |
| Specialty Medication Administration Site of Care | Jan 1, 2026 | Covered |
| Policy | Effective | Status of J2182 |
|---|---|---|
| Mepolizumab | Jun 15, 2026 | Covered |
| Specialty Medication Administration Site of Care | Jan 1, 2026 | Covered |
| Policy | Effective | Status of J2182 |
|---|---|---|
| Mepolizumab | Jun 15, 2026 | Covered |
| Specialty Medication Administration Site of Care | Jan 1, 2026 | Covered |
| Policy | Effective | Status of J2182 |
|---|---|---|
| Nucala (mepolizumab) Pre-filled Autoinjector and Syringe | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Nucala (mepolizumab) Pre-filled Autoinjector and Syringe | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2182 |
|---|---|---|
| Provider Administered Drugs – Site of Care | Oct 1, 2026 | Covered |
| Respiratory Interleukin-5 Inhibitor | Oct 1, 2026 | Covered |
| Policy | Effective | Status of J2182 |
|---|---|---|
| Interleukin-5 (IL-5) Antagonist (e.g., Cinqair, Exdensur, Nucala) and IL-5 Receptor Antagonist (e.g., Fasenra) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2182 |
|---|---|---|
| NUCALA (MEPOLIZUMAB) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2182 |
|---|---|---|
| Mepolizumab (Nucala) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2182 |
|---|---|---|
| Mepolizumab (Nucala) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2182 |
|---|---|---|
| Monoclonal Interleukin-5 Antagonists [mepolizumab (Nucala), reslizumab (Cinqair), and benralizumab (Fasenra)] | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2182 |
|---|---|---|
| Interleukin-5 (IL-5) Antagonist (e.g., Cinqair, Exdensur, Nucala) and IL-5 Receptor Antagonist (e.g., Fasenra) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2182 |
|---|---|---|
| 00501 mepolizumab (Nucala) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2182 |
|---|---|---|
| Nucala (mepolizumab) | Not recorded | Covered with conditionsInferred from policy title. Not listed in the policy document; attached because the policy title names the drug. |
| Policy | Effective | Status of J2182 |
|---|---|---|
| Respiratory Interleukin-5 Inhibitor | Oct 1, 2026 | Covered |